Otonomy Inc News Releases http://investors.otonomy.com/ Otonomy Inc News Releases en Otonomy to Present at the Raymond James Life Sciences and MedTech Conference http://investors.otonomy.com/news-releases/news-release-details/otonomy-present-raymond-james-life-sciences-and-medtech SAN DIEGO , June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber , Ph.D., president and chief executive officer, will present at the Raymond James Wed, 12 Jun 2019 08:00:00 -0400 Otonomy Inc News Releases 9106 Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update http://investors.otonomy.com/news-releases/news-release-details/otonomy-reports-first-quarter-2019-financial-results-and OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020 OTIPRIO ®  co-promotion agreement completed with Glenmark Therapeutics OTIVIDEX™  Phase 3 trial in Ménière’s disease on track for results in first half of 2020 OTO-413 Phase 1/2 trial in hearing loss expected to Mon, 06 May 2019 16:17:00 -0400 Otonomy Inc News Releases 9096 Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication http://investors.otonomy.com/news-releases/news-release-details/otonomy-announces-otiprior-co-promotion-agreement-glenmark SAN DIEGO , May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark Therapeutics Inc., USA , a wholly-owned subsidiary Thu, 02 May 2019 07:30:00 -0400 Otonomy Inc News Releases 9076 Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit http://investors.otonomy.com/news-releases/news-release-details/otonomy-participate-suntrust-robinson-humphrey-life-sciences SAN DIEGO , May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the company will host one-on-one meetings with investors at the 5th Annual SunTrust Robinson Humphrey Wed, 01 May 2019 07:30:00 -0400 Otonomy Inc News Releases 9071 Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update http://investors.otonomy.com/news-releases/news-release-details/otonomy-report-first-quarter-2019-financial-results-and-provide Webcast and Conference Call to be Held at 4:30 p.m. EDT on May 6, 2019 SAN DIEGO , April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results Mon, 29 Apr 2019 16:05:00 -0400 Otonomy Inc News Releases 9061 Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus http://investors.otonomy.com/news-releases/news-release-details/otonomy-initiates-phase-12-clinical-trial-oto-313-tinnitus Results expected in first half of 2020 SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-313, a Thu, 11 Apr 2019 07:30:00 -0400 Otonomy Inc News Releases 9051 Otonomy to Participate in Two Upcoming Investor Conferences http://investors.otonomy.com/news-releases/news-release-details/otonomy-participate-two-upcoming-investor-conferences SAN DIEGO , March 05, 2019 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber , Ph.D., president and chief executive officer, is scheduled to participate in two Tue, 05 Mar 2019 07:30:00 -0500 Otonomy Inc News Releases 9031 Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update http://investors.otonomy.com/news-releases/news-release-details/otonomy-reports-fourth-quarter-and-full-year-2018-financial OTIVIDEX™  Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019 OTO-413 Phase 1/2 trial in hearing loss expected to start in third quarter of 2019 $15 million term loan completed to extend cash Mon, 04 Mar 2019 16:18:00 -0500 Otonomy Inc News Releases 9016 Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update http://investors.otonomy.com/news-releases/news-release-details/otonomy-report-fourth-quarter-and-full-year-2018-financial Webcast and Conference Call to be Held at 4:30 p.m. EST on March 4, 2019 SAN DIEGO , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results Mon, 25 Feb 2019 16:05:00 -0500 Otonomy Inc News Releases 9001 Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting http://investors.otonomy.com/news-releases/news-release-details/otonomy-announces-multiple-presentations-association-research SAN DIEGO , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 42nd Annual Wed, 06 Feb 2019 07:30:00 -0500 Otonomy Inc News Releases 8981